HomeNewsIndiaINSACOG closely tracking new COVID-19 variant, presence not yet detected in India: Officials

INSACOG closely tracking new COVID-19 variant, presence not yet detected in India: Officials

The new variant, feared to have a high amount of spike mutations, has been detected in South Africa, with the authorities there confirming 22 positive cases associated with it on Thursday.

November 26, 2021 / 20:13 IST
Story continues below Advertisement
Representative Image (Reuters)
Representative Image (Reuters)

The Indian SARS-CoV-2 Genomics Consortium (INSACOG) is closely tracking the new variant of COVID-19 called B.1.1.529 and its presence has not been detected in the country yet, officials said on Friday.

The new variant, feared to have a high amount of spike mutations, has been detected in South Africa, with the authorities there confirming 22 positive cases associated with it on Thursday.

Story continues below Advertisement

Commenting on the development, a senior scientist with INSACOG said the consortium is closely tracking the new variant of COVID-19 called B.1.1.529 and its presence has not been detected yet in the country.

Health Ministry sources said INSACOG is “very closely monitoring” the situation to check for the presence of this variant and expedite the results of genomic analysis of positive samples of international travellers.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show